Citation: Farzad Fatehi, Yuliya N. Kyrychko, Konstantin B. Blyuss. Time-delayed model of autoimmune dynamics[J]. Mathematical Biosciences and Engineering, 2019, 16(5): 5613-5639. doi: 10.3934/mbe.2019279
[1] | Gaozhong Sun, Tongwei Zhao . Lung adenocarcinoma pathology stages related gene identification. Mathematical Biosciences and Engineering, 2020, 17(1): 737-746. doi: 10.3934/mbe.2020038 |
[2] | Shuyi Cen, Kaiyou Fu, Yue Shi, Hanliang Jiang, Jiawei Shou, Liangkun You, Weidong Han, Hongming Pan, Zhen Liu . A microRNA disease signature associated with lymph node metastasis of lung adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(3): 2557-2568. doi: 10.3934/mbe.2020140 |
[3] | Yuan Yang, Lingshan Zhou, Xi Gou, Guozhi Wu, Ya Zheng, Min Liu, Zhaofeng Chen, Yuping Wang, Rui Ji, Qinghong Guo, Yongning Zhou . Comprehensive analysis to identify DNA damage response-related lncRNA pairs as a prognostic and therapeutic biomarker in gastric cancer. Mathematical Biosciences and Engineering, 2022, 19(1): 595-611. doi: 10.3934/mbe.2022026 |
[4] | Bin Ma, Lianqun Cao, Yongmin Li . A novel 10-gene immune-related lncRNA signature model for the prognosis of colorectal cancer. Mathematical Biosciences and Engineering, 2021, 18(6): 9743-9760. doi: 10.3934/mbe.2021477 |
[5] | Ji-Ming Wu, Wang-Ren Qiu, Zi Liu, Zhao-Chun Xu, Shou-Hua Zhang . Integrative approach for classifying male tumors based on DNA methylation 450K data. Mathematical Biosciences and Engineering, 2023, 20(11): 19133-19151. doi: 10.3934/mbe.2023845 |
[6] | Jinqi He, Wenjing Zhang, Faxiang Li, Yan Yu . Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data. Mathematical Biosciences and Engineering, 2021, 18(5): 5959-5977. doi: 10.3934/mbe.2021298 |
[7] | Mengyang Han, Xiaoli Wang, Yaqi Li, Jianjun Tan, Chunhua Li, Wang Sheng . Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models. Mathematical Biosciences and Engineering, 2023, 20(6): 10626-10658. doi: 10.3934/mbe.2023470 |
[8] | Yanping Xie, Zhaohui Dong, Junhua Du, Xiaoliang Zang, Huihui Guo, Min Liu, Shengwen Shao . The relationship between mouse lung adenocarcinoma at different stages and the expression level of exosomes in serum. Mathematical Biosciences and Engineering, 2020, 17(2): 1548-1557. doi: 10.3934/mbe.2020080 |
[9] | Ziyu Wu, Sugui Wang, Qiang Li, Qingsong Zhao, Mingming Shao . Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma. Mathematical Biosciences and Engineering, 2020, 17(3): 2037-2047. doi: 10.3934/mbe.2020108 |
[10] | Siqi Hu, Fang Wang, Junjun Yang, Xingxiang Xu . Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma. Mathematical Biosciences and Engineering, 2023, 20(10): 18063-18082. doi: 10.3934/mbe.2023802 |
Baló's concentric sclerosis (BCS) was first described by Marburg [1] in 1906, but became more widely known until 1928 when the Hungarian neuropathologist Josef Baló published a report of a 23-year-old student with right hemiparesis, aphasia, and papilledema, who at autopsy had several lesions of the cerebral white matter, with an unusual concentric pattern of demyelination [2]. Traditionally, BCS is often regarded as a rare variant of multiple sclerosis (MS). Clinically, BCS is most often characterized by an acute onset with steady progression to major disability and death with months, thus resembling Marburg's acute MS [3,4]. Its pathological hallmarks are oligodendrocyte loss and large demyelinated lesions characterized by the annual ring-like alternating pattern of demyelinating and myelin-preserved regions. In [5], the authors found that tissue preconditioning might explain why Baló lesions develop a concentric pattern. According to the tissue preconditioning theory and the analogies between Baló's sclerosis and the Liesegang periodic precipitation phenomenon, Khonsari and Calvez [6] established the following chemotaxis model
˜uτ=DΔX˜u⏟diffusion ofactivated macrophages−∇X⋅(˜χ˜u(ˉu−˜u)∇˜v)⏟chemoattractant attractssurrounding activated macrophages+μ˜u(ˉu−˜u)⏟production of activated macrophages,−˜ϵΔX˜v⏟diffusion of chemoattractant=−˜α˜v+˜β˜w⏟degradation∖production of chemoattractant,˜wτ=κ˜uˉu+˜u˜u(ˉw−˜w)⏟destruction of oligodendrocytes, | (1.1) |
where ˜u, ˜v and ˜w are, respectively, the density of activated macrophages, the concentration of chemoattractants and density of destroyed oligodendrocytes. ˉu and ˉw represent the characteristic densities of macrophages and oligodendrocytes respectively.
By numerical simulation, the authors in [6,7] indicated that model (1.1) only produces heterogeneous concentric demyelination and homogeneous demyelinated plaques as χ value gradually increases. In addition to the chemoattractant produced by destroyed oligodendrocytes, "classically activated'' M1 microglia also can release cytotoxicity [8]. Therefore we introduce a linear production term into the second equation of model (1.1), and establish the following BCS chemotaxis model with linear production term
{˜uτ=DΔX˜u−∇X⋅(˜χ˜u(ˉu−˜u)∇˜v)+μ˜u(ˉu−˜u),−˜ϵΔX˜v+˜α˜v=˜β˜w+˜γ˜u,˜wτ=κ˜uˉu+˜u˜u(ˉw−˜w). | (1.2) |
Before going to details, let us simplify model (1.2) with the following scaling
u=˜uˉu,v=μˉu˜ϵD˜v,w=˜wˉw,t=μˉuτ,x=√μˉuDX,χ=˜χ˜ϵμ,α=D˜α˜ϵμˉu,β=˜βˉw,γ=˜γˉu,δ=κμ, |
then model (1.2) takes the form
{ut=Δu−∇⋅(χu(1−u)∇v)+u(1−u),x∈Ω,t>0,−Δv+αv=βw+γu,x∈Ω,t>0,wt=δu1+uu(1−w),x∈Ω,t>0,∂ηu=∂ηv=0,x∈∂Ω,t>0,u(x,0)=u0(x),w(x,0)=w0(x),x∈Ω, | (1.3) |
where Ω⊂Rn(n≥1) is a smooth bounded domain, η is the outward normal vector to ∂Ω, ∂η=∂/∂η, δ balances the speed of the front and the intensity of the macrophages in damaging the myelin. The parameters χ,α and δ are positive constants as well as β,γ are nonnegative constants.
If δ=0, then model (1.3) is a parabolic-elliptic chemotaxis system with volume-filling effect and logistic source. In order to be more line with biologically realistic mechanisms, Hillen and Painter [9,10] considered the finite size of individual cells-"volume-filling'' and derived volume-filling models
{ut=∇⋅(Du(q(u)−q′(u)u)∇u−q(u)uχ(v)∇v)+f(u,v),vt=DvΔv+g(u,v). | (1.4) |
q(u) is the probability of the cell finding space at its neighbouring location. It is also called the squeezing probability, which reflects the elastic properties of cells. For the linear choice of q(u)=1−u, global existence of solutions to model (1.4) in any space dimension are investigated in [9]. Wang and Thomas [11] established the global existence of classical solutions and given necessary and sufficient conditions for spatial pattern formation to a generalized volume-filling chemotaxis model. For a chemotaxis system with generalized volume-filling effect and logistic source, the global boundedness and finite time blow-up of solutions are obtained in [12]. Furthermore, the pattern formation of the volume-filling chemotaxis systems with logistic source and both linear diffusion and nonlinear diffusion are shown in [13,14,15] by the weakly nonlinear analysis. For parabolic-elliptic Keller-Segel volume-filling chemotaxis model with linear squeezing probability, asymptotic behavior of solutions is studied both in the whole space Rn [16] and on bounded domains [17]. Moreover, the boundedness and singularity formation in parabolic-elliptic Keller-Segel volume-filling chemotaxis model with nonlinear squeezing probability are discussed in [18,19].
Very recently, we [20] investigated the uniform boundedness and global asymptotic stability for the following chemotaxis model of multiple sclerosis
{ut=Δu−∇⋅(χ(u)∇v)+u(1−u),χ(u)=χu1+u,x∈Ω,t>0,τvt=Δv−βv+αw+γu,x∈Ω,t>0,wt=δu1+uu(1−w),x∈Ω,t>0, |
subject to the homogeneous Neumann boundary conditions.
In this paper, we are first devoted to studying the local existence and uniform boundedness of the unique classical solution to system (1.3) by using Neumann heat semigroup arguments, Banach fixed point theorem, parabolic Schauder estimate and elliptic regularity theory. Then we discuss that exponential asymptotic stability of the positive equilibrium point to system (1.3) by constructing Lyapunov function.
Although, in the pathological mechanism of BCS, the initial data in model (1.3) satisfy 0<u0(x)≤1,w0(x)=0, we mathematically assume that
{u0(x)∈C0(ˉΩ)with0≤,≢u0(x)≤1inΩ,w0(x)∈C2+ν(ˉΩ)with0<ν<1and0≤w0(x)≤1inΩ. | (1.5) |
It is because the condition (1.5) implies u(x,t0)>0 for any t0>0 by the strong maximum principle.
The following theorems give the main results of this paper.
Theorem 1.1. Assume that the initial data (u0(x),w0(x)) satisfy the condition (1.5). Then model (1.3) possesses a unique global solution (u(x,t),v(x,t),w(x,t)) satisfying
u(x,t)∈C0(ˉΩ×[0,∞))∩C2,1(ˉΩ×(0,∞)),v(x,t)∈C0((0,∞),C2(ˉΩ)),w(x,t)∈C2,1(ˉΩ×[0,∞)), | (1.6) |
and
0<u(x,t)≤1,0≤v(x,t)≤β+γα,w0(x)≤w(x,t)≤1,inˉΩ×(0,∞). |
Moreover, there exist a ν∈(0,1) and M>0 such that
‖u‖C2+ν,1+ν/2(ˉΩ×[1,∞))+‖v‖C0([1,∞),C2+ν(ˉΩ))+‖w‖Cν,1+ν/2(ˉΩ×[1,∞))≤M. | (1.7) |
Theorem 1.2. Assume that β≥0,γ≥0,β+γ>0 and
χ<{min{2√2αβ,2√2αγ},β>0,γ>0,2√2αβ,β>0,γ=0,2√2αγ,β=0,γ>0. | (1.8) |
Let (u,v,w) be a positive classical solution of the problem (1.3), (1.5). Then
‖u(⋅,t)−u∗‖L∞(Ω)+‖v(⋅,t)−v∗‖L∞(Ω)+‖w(⋅,t)−w∗‖L∞(Ω)→0,ast→∞. | (1.9) |
Furthermore, there exist positive constants λ=λ(χ,α,γ,δ,n) and C=C(|Ω|,χ,α,β,γ,δ) such that
‖u−u∗‖L∞(Ω)≤Ce−λt,‖v−v∗‖L∞(Ω)≤Ce−λt,‖w−w∗‖L∞(Ω)≤Ce−λt,t>0, | (1.10) |
where (u∗,v∗,w∗)=(1,β+γα,1) is the unique positive equilibrium point of the model (1.3).
The paper is organized as follows. In section 2, we prove the local existence, the boundedness and global existence of a unique classical solution. In section 3, we firstly establish the uniform convergence of the positive global classical solution, then discuss the exponential asymptotic stability of positive equilibrium point in the case of weak chemotactic sensitivity. The paper ends with a brief concluding remarks.
The aim of this section is to develop the existence and boundedness of a global classical solution by employing Neumann heat semigroup arguments, Banach fixed point theorem, parabolic Schauder estimate and elliptic regularity theory.
Proof of Theorem 1.1 (ⅰ) Existence. For p∈(1,∞), let A denote the sectorial operator defined by
Au:=−Δuforu∈D(A):={φ∈W2,p(Ω)|∂∂ηφ|∂Ω=0}. |
λ1>0 denote the first nonzero eigenvalue of −Δ in Ω with zero-flux boundary condition. Let A1=−Δ+α and Xl be the domains of fractional powers operator Al,l≥0. From the Theorem 1.6.1 in [21], we know that for any p>n and l∈(n2p,12),
‖z‖L∞(Ω)≤C‖Al1z‖Lp(Ω)forallz∈Xl. | (2.1) |
We introduce the closed subset
S:={u∈X|‖u‖L∞((0,T);L∞(Ω))≤R+1} |
in the space X:=C0([0,T];C0(ˉΩ)), where R is a any positive number satisfying
‖u0(x)‖L∞(Ω)≤R |
and T>0 will be specified later. Note F(u)=u1+u, we consider an auxiliary problem with F(u) replaced by its extension ˜F(u) defined by
˜F(u)={F(u)uifu≥0,−F(−u)(−u)ifu<0. |
Notice that ˜F(u) is a smooth globally Lipshitz function. Given ˆu∈S, we define Ψˆu=u by first writing
w(x,t)=(w0(x)−1)e−δ∫t0˜F(ˆu)ˆuds+1,x∈Ω,t>0, | (2.2) |
and
w0≤w(x,t)≤1,x∈Ω,t>0, |
then letting v solve
{−Δv+αv=βw+γˆu,x∈Ω,t∈(0,T),∂ηv=0,x∈∂Ω,t∈(0,T), | (2.3) |
and finally taking u to be the solution of the linear parabolic problem
{ut=Δu−χ∇⋅(ˆu(1−ˆu)∇v)+ˆu(1−ˆu),x∈Ω,t∈(0,T),∂ηu=0,x∈∂Ω,t∈(0,T),u(x,0)=u0(x),x∈Ω. |
Applying Agmon-Douglas-Nirenberg Theorem [22,23] for the problem (2.3), there exists a constant C such that
‖v‖W2p(Ω)≤C(β‖w‖Lp(Ω)+γ‖ˆu‖Lp(Ω))≤C(β|Ω|1p+γ(R+1)) | (2.4) |
for all t∈(0,T). From a variation-of-constants formula, we define
Ψ(ˆu)=etΔu0−χ∫t0e(t−s)Δ∇⋅(ˆu(1−ˆu)∇v(s))ds+∫t0e(t−s)Δˆu(s)(1−ˆu(s))ds. |
First we shall show that for T small enough
‖Ψ(ˆu)‖L∞((0,T);L∞(Ω))≤R+1 |
for any ˆu∈S. From the maximum principle, we can give
‖etΔu0‖L∞(Ω)≤‖u0‖L∞(Ω), | (2.5) |
and
∫t0‖etΔˆu(s)(1−ˆu(s))‖L∞(Ω)ds≤∫t0‖ˆu(s)(1−ˆu(s))‖L∞(Ω)ds≤(R+1)(R+2)T | (2.6) |
for all t∈(0,T). We use inequalities (2.1) and (2.4) to estimate
χ∫t0‖e(t−s)Δ∇⋅(ˆu(1−ˆu)∇v(s))‖L∞(Ω)ds≤C∫t0(t−s)−l‖et−s2Δ∇⋅(ˆu(1−ˆu)∇v(s))‖Lp(Ω)ds≤C∫t0(t−s)−l−12‖(ˆu(1−ˆu)∇v(s)‖Lp(Ω)ds≤CT12−l(R+1)(R+2)(β|Ω|1p+γ(R+1)) | (2.7) |
for all t∈(0,T). This estimate is attributed to T<1 and the inequality in [24], Lemma 1.3 iv]
‖etΔ∇z‖Lp(Ω)≤C1(1+t−12)e−λ1t‖z‖Lp(Ω)forallz∈C∞c(Ω). |
From inequalities (2.5), (2.6) and (2.7) we can deduce that Ψ maps S into itself for T small enough.
Next we prove that the map Ψ is a contractive on S. For ˆu1,ˆu2∈S, we estimate
‖Ψ(ˆu1)−Ψ(ˆu2)‖L∞(Ω)≤χ∫t0(t−s)−l−12‖[ˆu2(s)(1−ˆu2(s))−ˆu1(s)(1−ˆu1(s))]∇v2(s)‖Lp(Ω)ds+χ∫t0‖ˆu1(s)(1−ˆu1(s))(∇v1(s)−∇v2(s))‖Lp(Ω)ds+∫t0‖e(t−s)Δ[ˆu1(s)(1−ˆu1(s))−ˆu2(s)(1−ˆu2(s))]‖L∞(Ω)ds≤χ∫t0(t−s)−l−12(2R+1)‖ˆu1(s)−ˆu2(s)‖X‖∇v2(s)‖Lp(Ω)ds+χ∫t0(R+1)(R+2)(β‖w1(s)−w2(s)‖Lp(Ω)+γ‖ˆu1(s)−ˆu2(s)‖Lp(Ω))ds+∫t0(2R+1)‖ˆu1(s)−ˆu2(s)‖Xds≤χ∫t0(t−s)−l−12(2R+1)‖ˆu1(s)−ˆu2(s)‖X‖∇v2(s)‖Lp(Ω)ds+2βδχ∫t0(R+1)(R+2)t‖ˆu1(s)−ˆu2(s)‖Lp(Ω)+γ‖ˆu1(s)−ˆu2(s)‖Lp(Ω)ds+∫t0(2R+1)‖ˆu1(s)−ˆu2(s)‖Xds≤(CχT12−l(2R+1)(β|Ω|1p+γ(R+1))+2βδχT(R2+3R+γ+2)+T(2R+1))‖ˆu1(s)−ˆu2(s)‖X. |
Fixing T∈(0,1) small enough such that
(CχT12−l(2R+1)(β|Ω|1p+γ(R+1))+2βδχT(R2+3R+γ+2)+T(2R+1))≤12. |
It follows from the Banach fixed point theorem that there exists a unique fixed point of Ψ.
(ⅱ) Regularity. Since the above of T depends on ‖u0‖L∞(Ω) and ‖w0‖L∞(Ω) only, it is clear that (u,v,w) can be extended up to some maximal Tmax∈(0,∞]. Let QT=Ω×(0,T] for all T∈(0,Tmax). From u∈C0(ˉQT), we know that w∈C0,1(ˉQT) by the expression (2.2) and v∈C0([0,T],W2p(Ω)) by Agmon-Douglas-Nirenberg Theorem [22,23]. From parabolic Lp-estimate and the embedding relation W1p(Ω)↪Cν(ˉΩ),p>n, we can get u∈W2,1p(QT). By applying the following embedding relation
W2,1p(QT)↪Cν,ν/2(ˉQT),p>n+22, | (2.8) |
we can derive u(x,t)∈Cν,ν/2(ˉQT) with 0<ν≤2−n+2p. The conclusion w∈Cν,1+ν/2(ˉQT) can be obtained by substituting u∈Cν,ν/2(ˉQT) into the formulation (2.2). The regularity u∈C2+ν,1+ν/2(ˉQT) can be deduced by using further bootstrap argument and the parabolic Schauder estimate. Similarly, we can get v∈C0((0,T),C2+ν(ˉΩ)) by using Agmon-Douglas-Nirenberg Theorem [22,23]. From the regularity of u we have w∈C2+ν,1+ν/2(ˉQT).
Moreover, the maximal principle entails that 0<u(x,t)≤1, 0≤v(x,t)≤β+γα. It follows from the positivity of u that ˜F(u)=F(u) and because of the uniqueness of solution we infer the existence of the solution to the original problem.
(ⅲ) Uniqueness. Suppose (u1,v1,w1) and (u2,v2,w2) are two deferent solutions of model (1.3) in Ω×[0,T]. Let U=u1−u2, V=v1−v2, W=w1−w2 for t∈(0,T). Then
12ddt∫ΩU2dx+∫Ω|∇U|2dx≤χ∫Ω|u1(1−u1)−u2(1−u2)|∇v1||∇U|+u2(1−u2)|∇V||∇U|dx+∫Ω|u1(1−u1)−u2(1−u2)||U|dx≤χ∫Ω|U||∇v1||∇U|+14|∇V||∇U|dx+∫Ω|U|2dx≤∫Ω|∇U|2dx+χ232∫Ω|∇V|2dx+χ2K2+22∫Ω|U|2dx, | (2.9) |
where we have used that |∇v1|≤K results from ∇v1∈C0([0,T],C0(ˉΩ)).
Similarly, by Young inequality and w0≤w1≤1, we can estimate
∫Ω|∇V|2dx+α2∫Ω|V|2dx≤β2α∫Ω|W|2dx+γ2α∫Ω|U|2dx, | (2.10) |
and
ddt∫ΩW2dx≤δ∫Ω|U|2+|W|2dx. | (2.11) |
Finally, adding to the inequalities (2.9)–(2.11) yields
ddt(∫ΩU2dx+∫ΩW2dx)≤C(∫ΩU2dx+∫ΩW2dx)forallt∈(0,T). |
The results U≡0, W≡0 in Ω×(0,T) are obtained by Gronwall's lemma. From the inequality (2.10), we have V≡0. Hence (u1,v1,w1)=(u2,v2,w2) in Ω×(0,T).
(ⅳ) Uniform estimates. We use the Agmon-Douglas-Nirenberg Theorem [22,23] for the second equation of the model (1.3) to get
‖v‖C0([t,t+1],W2p(Ω))≤C(‖u‖Lp(Ω×[t,t+1])+‖w‖Lp(Ω×[t,t+1]))≤C2 | (2.12) |
for all t≥1 and C2 is independent of t. From the embedded relationship W1p(Ω)↪C0(ˉΩ),p>n, the parabolic Lp-estimate and the estimation (2.12), we have
‖u‖W2,1p(Ω×[t,t+1])≤C3 |
for all t≥1. The estimate ‖u‖Cν,ν2(ˉΩ×[t,t+1])≤C4 for all t≥1 obtained by the embedded relationship (2.8). We can immediately compute ‖w‖Cν,1+ν2(ˉΩ×[t,t+1])≤C5 for all t≥1 according to the regularity of u and the specific expression of w. Further, bootstrapping argument leads to ‖v‖C0([t,t+1],C2+ν(ˉΩ))≤C6 and ‖u‖C2+ν,1+ν2(ˉΩ×[t,t+1])≤C7 for all t≥1. Thus the uniform estimation (1.7) is proved.
Remark 2.1. Assume the initial data 0<u0(x)≤1 and w0(x)=0. Then the BCS model (1.3) has a unique classical solution.
In this section we investigate the global asymptotic stability of the unique positive equilibrium point (1,β+γα,1) to model (1.3). To this end, we first introduce following auxiliary problem
{uϵt=Δuϵ−∇⋅(uϵ(1−uϵ)∇vϵ)+uϵ(1−uϵ),x∈Ω,t>0,−Δvϵ+αvϵ=βwϵ+γuϵ,x∈Ω,t>0,wϵt=δu2ϵ+ϵ1+uϵ(1−wϵ),x∈Ω,t>0,∂ηuϵ=∂ηvϵ=0,x∈∂Ω,t>0,uϵ(x,0)=u0(x),wϵ(x,0)=w0(x),x∈Ω. | (3.1) |
By a similar proof of Theorem 1.1, we get that the problem (3.1) has a unique global classical solution (uϵ,vϵ,wϵ), and there exist a ν∈(0,1) and M1>0 which is independent of ϵ such that
‖uϵ‖C2+ν,1+ν/2(ˉΩ×[1,∞))+‖vϵ‖C2+ν,1+ν/2(ˉΩ×[1,∞))+‖wϵ‖Cν,1+ν/2(ˉΩ×[1,∞))≤M1. | (3.2) |
Then, motivated by some ideas from [25,26], we construct a Lyapunov function to study the uniform convergence of homogeneous steady state for the problem (3.1).
Let us give following lemma which is used in the proof of Lemma 3.2.
Lemma 3.1. Suppose that a nonnegative function f on (1,∞) is uniformly continuous and ∫∞1f(t)dt<∞. Then f(t)→0 as t→∞.
Lemma 3.2. Assume that the condition (1.8) is satisfied. Then
‖uϵ(⋅,t)−1‖L2(Ω)+‖vϵ(⋅,t)−v∗‖L2(Ω)+‖wϵ(⋅,t)−1‖L2(Ω)→0,t→∞, | (3.3) |
where v∗=β+γα.
Proof We construct a positive function
E(t):=∫Ω(uε−1−lnuϵ)+12δϵ∫Ω(wϵ−1)2,t>0. |
From the problem (3.1) and Young's inequality, we can compute
ddtE(t)≤χ24∫Ω|∇vϵ|2dx−∫Ω(uϵ−1)2dx−∫Ω(wϵ−1)2dx,t>0. | (3.4) |
We multiply the second equations in system (3.1) by vϵ−v∗, integrate by parts over Ω and use Young's inequality to obtain
∫Ω|∇vϵ|2dx≤γ22α∫Ω(uϵ−1)2dx+β22α∫Ω(wϵ−1)2dx,t>0, | (3.5) |
and
∫Ω(vϵ−v∗)2dx≤2γ2α2∫Ω(uϵ−1)2dx+2β2α2∫Ω(wϵ−1)2dx,t>0. | (3.6) |
Substituting inequality (3.5) into inequality (3.4) to get
ddtE(t)≤−C8(∫Ω(uϵ−1)2dx+∫Ω(wϵ−1)2dx),t>0, |
where C8=min{1−χ2β28α,1−χ2γ28α}>0.
Let f(t):=∫Ω(uϵ−1)2+(wϵ−1)2dx. Then
∫∞1f(t)dt≤E(1)C8<∞,t>1. |
It follows from the uniform estimation (3.2) and the Arzela-Ascoli theorem that f(t) is uniformly continuous in (1,∞). Applying Lemma 3.1, we have
∫Ω(uϵ(⋅,t)−1)2+(wϵ(⋅,t)−1)2dx→0,t→∞. | (3.7) |
Combining inequality (3.6) and the limit (3.7) to obtain
∫Ω(vϵ(⋅,t)−v∗)2dx→0,t→∞. |
Proof of Theorem 1.2 As we all known, each bounded sequence in C2+ν,1+ν2(ˉΩ×[1,∞)) is precompact in C2,1(ˉΩ×[1,∞)). Hence there exists some subsequence {uϵn}∞n=1 satisfying ϵn→0 as n→∞ such that
limn→∞‖uϵn−u∗‖C2,1(ˉΩ×[1,∞))=0. |
Similarly, we can get
limn→∞‖vϵn−v∗‖C2(ˉΩ)=0, |
and
limn→∞‖wϵn−w∗‖C0,1(ˉΩ×[1,∞))=0. |
Combining above limiting relations yields that (u∗,v∗,w∗) satisfies model (1.3). The conclusion (u∗,v∗,w∗)=(u,v,w) is directly attributed to the uniqueness of the classical solution of the model (1.3). Furthermore, according to the conclusion, the strong convergence (3.3) and Diagonal line method, we can deduce
‖u(⋅,t)−1‖L2(Ω)+‖v(⋅,t)−v∗‖L2(Ω)+‖w(⋅,t)−1‖L2(Ω)→0,t→∞. | (3.8) |
By applying Gagliardo-Nirenberg inequality
‖z‖L∞≤C‖z‖2/(n+2)L2(Ω)‖z‖n/(n+2)W1,∞(Ω),z∈W1,∞(Ω), | (3.9) |
comparison principle of ODE and the convergence (3.8), the uniform convergence (1.9) is obtained immediately.
Since limt→∞‖u(⋅,t)−1‖L∞(Ω)=0, so there exists a t1>0 such that
u(x,t)≥12forallx∈Ω,t>t1. | (3.10) |
Using the explicit representation formula of w
w(x,t)=(w0(x)−1)e−δ∫t0F(u)uds+1,x∈Ω,t>0 |
and the inequality (3.10), we have
‖w(⋅,t)−1‖L∞(Ω)≤e−δ6(t−t1),t>t1. | (3.11) |
Multiply the first two equations in model (1.3) by u−1 and v−v∗, respectively, integrate over Ω and apply Cauchy's inequality, Young's inequality and the inequality (3.10), to find
ddt∫Ω(u−1)2dx≤χ232∫Ω|∇v|2dx−∫Ω(u−1)2dx,t>t1. | (3.12) |
∫Ω|∇v|2dx+α2∫Ω(v−v∗)2dx≤β2α∫Ω(w−1)2dx+γ2α∫Ω(u−1)2dx,t>0. | (3.13) |
Combining the estimations (3.11)–(3.13) leads us to the estimate
ddt∫Ω(u−1)2dx≤(χ2γ232α−1)∫Ω(u−1)2dx+χ2β232αe−δ3(t−t1),t>t1. |
Let y(t)=∫Ω(u−1)2dx. Then
y′(t)≤(χ2γ232α−1)y(t)+χ2β232αe−δ3(t−t1),t>t1. |
From comparison principle of ODE, we get
y(t)≤(y(t1)−3χ2β232α(3−δ)−χ2γ2)e−(1−χ2γ232α)(t−t1)+3χ2β232α(3−δ)−χ2γ2e−δ3(t−t1),t>t1. |
This yields
∫Ω(u−1)2dx≤C9e−λ2(t−t1),t>t1, | (3.14) |
where λ2=min{1−χ2γ232α,δ3} and C9=max{|Ω|−3χ2β232α(3−δ)−χ2γ2,3χ2β232α(3−δ)−χ2γ2}.
From the inequalities (3.11), (3.13) and (3.14), we derive
∫Ω(v−β+γα)2dx≤C10e−λ2(t−t1),t>t1, | (3.15) |
where C10=max{2γ2α2C9,2β2α2}. By employing the uniform estimation (1.7), the inequalities (3.9), (3.14) and (3.15), the exponential decay estimation (1.10) can be obtained.
The proof is complete.
In this paper, we mainly study the uniform boundedness of classical solutions and exponential asymptotic stability of the unique positive equilibrium point to the chemotactic cellular model (1.3) for Baló's concentric sclerosis (BCS). For model (1.1), by numerical simulation, Calveza and Khonsarib in [7] shown that demyelination patterns of concentric rings will occur with increasing of chemotactic sensitivity. By the Theorem 1.1 we know that systems (1.1) and (1.2) are {uniformly} bounded and dissipative. By the Theorem 1.2 we also find that the constant equilibrium point of model (1.1) is exponentially asymptotically stable if
˜χ<2ˉw˜β√2Dμ˜α˜ϵˉu, |
and the constant equilibrium point of the model (1.2) is exponentially asymptotically stable if
˜χ<2√2Dμ˜α˜ϵˉumin{1ˉw˜β,1ˉu˜γ}. |
According to a pathological viewpoint of BCS, the above stability results mean that if chemoattractive effect is weak, then the destroyed oligodendrocytes form a homogeneous plaque.
The authors would like to thank the editors and the anonymous referees for their constructive comments. This research was supported by the National Natural Science Foundation of China (Nos. 11761063, 11661051).
We have no conflict of interest in this paper.
[1] | A. K. Abbas, A. H. H. Lichtman and S. Pillai, Cellular and Molecular Immunology, Elsevier Health Sciences, 2015. |
[2] | D. Mason, A very high level of crossreactivity is an essential feature of the T-cell receptor, Immunol. Today, 19 (1998), 395–404. |
[3] | E. M. Shevach, R. S. McHugh, C. A. Piccirillo, et al., Control of T-cell activation by CD4+CD25+ suppressor T cells, Immunol. Rev., 182 (2001), 58–67. |
[4] | A. M. Thornton and E. M. Shevach, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production, J. Exp. Med., 188 (1998), 287–296. |
[5] | A. Corthay, How do regulatory T cells work?, Scand. J. Immunol., 70 (2009), 326–336. |
[6] | D. Buljevac, H. Z. Flach, W. C. J. Hop, et al., Prospective study on the relationship between infections and multiple sclerosis exacerbations, Brain, 125 (2002), 952–960. |
[7] | D. Germolic, D. H. Kono, J. C. Pfau, et al., Animal models used to examine the role of environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop, J. Autoimmun., 39 (2012), 285–293. |
[8] | M. P. Mallampalli, E. Davies, D. Wood, et al., Role of environment and sex differences in the development of autoimmune disease: a roundtable meeting report, J. Womens Health, 22 (2013), 578–586. |
[9] | B. Krone and J. M. Grange, Multiple sclerosis: are protective immune mechanisms compromised by a complex infectious background?, Autoimmune Dis., 2011 (2010), 708750. |
[10] | M. Ohashi, N. Orlova, C. Quink, et al., Cloning of the Epstein-Barr virus-related rhesus lymphocryptovirus as a bacterial artificial chromosome: a loss-of-function mutation of the rhBARF1 immune evasion gene, J. Virol., 85 (2011), 1330–1339. |
[11] | D. Hober and P. Sauter, Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host, Nat. Rev. Endocrinol., 6 (2010), 279–289. |
[12] | S. E. Myers, L. Brewer, D. P. Shaw, et al., Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor, Xenotransplantation, 11 (2004), 536–546. |
[13] | K. Döhner, K. Radtke, S. Schmidt, et al., Eclipse phase of herpes simplex virus type 1 infection: Efficient dynein-mediated capsid transport without the small capsid protein VP26, J. Virol., 80 (2006), 8211–8224. |
[14] | U. Maurer, B. Sodeik and K. Gruenewald, Native 3D intermediates of membrane fusion in herpes simplex virus 1 entry, Proc. Natl. Acad. Sci. USA, 105 (2008), 10559–10564. |
[15] | S. Manfredo Vieira, M. Hiltensperger, V. Kumar, et al., Translocation of a gut pathobiont drives autoimmunity in mice and humans, Science, 359 (2018), 1156–1161. |
[16] | R. S. Fujinami, Can virus infections trigger autoimmune disease?, J. Autoimmun., 16 (2001), 229–234. |
[17] | A. M. Ercolini and S. D. Miller, The role of infections in autoimmune disease, Clin. Exp. Immunol., 155 (2009), 1–15. |
[18] | R. S. Fujinami, M. G. von Herrath, U. Christen, et al., Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease, Clin. Microbiol. Rev., 19 (2006), 80–94. |
[19] | R. S. Fujinami, M. B. Oldstone, Z. Wroblewska, et al., Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments, Proc. Natl. Acad. Sci. USA, 80 (1983), 2346–2350. |
[20] | M. G. von Herrath and M. B. A. Oldstone, Virus-induced autoimmune disease, Curr. Opin. Immunol., 8 (1996), 878–885. |
[21] | C. Münz, J. D. Lünemann, M. T. Getts, et al., Antiviral immune responses: triggers of or triggered by autoimmunity?, Nat. Rev. Immunol., 9 (2009), 246. |
[22] | S. Bonhoeffer, R. M. May, G. M. Shaw, et al., Virus dynamics and drug therapy, Proc. Natl. Acad. Sci. USA, 94 (1997), 6971–6976. |
[23] | M. A. Nowak and C. R. Bangham, Population dynamics of immune responses to persistent viruses, Science-AAAS-Weekly Paper Edition, 272 (1996), 74–79. |
[24] | A. S. Perelson, Viral kinetics and mathematical models, Am. J. Med., 107 (Suppl 2) (1999), 49–52. |
[25] | A. S. Perelson, Modelling viral and immune system dynamics, Nat. Rev. Immunol., 2 (2002), 28–36. |
[26] | P. Baccam, C. Beauchemin, C. A. Macken, et al., Kinetics of influenza A infection in humans, J. Virol., 80 (2006), 7590–7599. |
[27] | C. A. A. Beauchemin, J. J. McSharry, G. L. Drusano, et al., Modeling amantadine treatment of influenza A virus in vitro, J. Theor. Biol., 254 (2008), 439–451. |
[28] | C. A. A. Beauchemin and A. Handel, A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead, BMC Public Health, 11 (Suppl 1) (2011), S7. |
[29] | A. S. Perelson, A. Neumann, M. Markowitz, et al., HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science, 271 (1996), 1582–1586. |
[30] | A. S. Perelson, P. Essunger, Y. Cao, et al., Decay characteristics of HIV-1 infected compartments during combination therapy, Nature, 387 (1997), 188–191. |
[31] | M. A. Nowak, S. Bonhoeffer, A. M. Hill, et al., Viral dynamics in hepatitis b virus infection, Proc. Natl. Acad. Sci. USA, 93 (1996), 4398–4402. |
[32] | A. U. Neumann, N. P. Lam, H. Dahari, et al., Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science, 282 (1998), 103–107. |
[33] | A. U. Neumann, N. P. Lam, H. Dahari, et al., Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus, J. Infect. Dis., 182 (2000), 28–35. |
[34] | R. M. Ribeiro, J. Layden-Almer, K. A. Powers, et al., Dynamics of alanine aminotransferase during hepatitis C virus treatment, Hepatology, 38 (2003), 509–517. |
[35] | L. A. Segel, E. Jäger, D. Elias, et al., A quantitative model of autoimmune disease and T-cell vaccination: does more mean less?, Immunol. Today, 16 (1995), 80–84. |
[36] | J. A. M. Borghans and R. J. De Boer, A minimal model for T-cell vaccination, Proc. R. Soc. Lond. B Biol. Sci., 259 (1995), 173–178. |
[37] | J. A. M. Borghans, R. J. De Boer, E. Sercarz, et al., T cell vaccination in experimental autoimmune encephalomyelitis: a mathematical model, J. Immunol., 161 (1998), 1087–1093. |
[38] | S. Iwami, Y. Takeuchi, Y. Miura, et al., Dynamical properties of autoimmune disease models: tolerance, flare-up, dormancy, J. Theor. Biol., 246 (2007), 646–659. |
[39] | S. Iwami, Y. Takeuchi, K. Iwamoto, et al., A mathematical design of vector vaccine against autoimmune disease, J. Theor. Biol., 256 (2009), 382–392. |
[40] | K. León, R. Perez, A. Lage, et al., Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates, J. Theor. Biol., 207 (2000), 231–254. |
[41] | K. León, A. Lage and J. Carneiro, Tolerance and immunity in a mathematical model of T-cell mediated suppression, J. Theor. Biol., 225 (2003), 107–126. |
[42] | K. León, J. Faro, A. Lage, et al., Inverse correlation between the incidences of autoimmune disease and infection predicted by a model of T cell mediated tolerance, J. Autoimmun., 22 (2004), 31–42. |
[43] | J. Carneiro, T. Paixão, D. Milutinovic, et al., Immunological self-tolerance: lessons from mathematical modeling, J. Comput. Appl. Math., 184 (2005), 77–100. |
[44] | D. Wodarz and V. A. A. Jansen, A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology, Immunol. Lett., 86 (2003), 213–227. |
[45] | R. Root-Bernstein, Theories and modeling of autoimmunity, J. Theor. Biol., 375 (2015), 1–124. |
[46] | J. D. Fontenot, M. A. Gavin and A. Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells, Nat. Immunol., 4 (2003), 330–336. |
[47] | S. Sakaguchi, Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses, Annu. Rev. Immunol., 22 (2004), 531–562. |
[48] | S. Z. Josefowicz, L. F. Lu and A. Y. Rudensky, Regulatory T cells: Mechanisms of differentiation and function, Annu. Rev. Immunol., 30 (2012), 531–564. |
[49] | H. K. Alexander and L. M. Wahl, Self-tolerance and autoimmunity in a regulatory T cell model, Bull. Math. Biol., 73 (2011), 33–71. |
[50] | N. J. Burroughs, M. Ferreira, B. M. P. M. Oliveira, et al., A transcritical bifurcation in an immune response model, J. Differ. Equ. Appl., 17 (2011), 1101–1106. |
[51] | N. J. Burroughs, M. Ferreira, B. M. P. M. Oliveira, et al., Autoimmunity arising from bystander proliferation of T cells in an immune response model, Math. Comput. Model., 53 (2011), 1389–1393. |
[52] | Z. Grossman and W. E. Paul, Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses, Proc. Natl. Acad. Sci. USA, 89 (1992), 10365–10369. |
[53] | Z. Grossman and A. Singer, Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus, Proc. Natl. Acad. Sci. USA, 93 (1996), 14747–14752. |
[54] | Z. Grossman and W. E. Paul, Self-tolerance: context dependent tuning of T cell antigen recognition, Semin. Immunol., 12 (2000), 197–203. |
[55] | A. J. Noest, Designing lymphocyte functional structure for optimal signal detection: voilá, T cells, J. Theor. Biol., 207 (2000), 195–216. |
[56] | D. A. Peterson, R. J. DiPaolo, O. Kanagawa, et al., Cutting edge: negative selection of immature thymocytes by a few peptide-MHC complexes: differential sensitivity of immature and mature T cells, J. Immunol., 162 (1999), 3117–3120. |
[57] | L. B. Nicholson, A. C. Anderson and V. K. Kuchroo, Tuning T cell activation threshold and effector function with cross-reactive peptide ligands, Int. Immunol., 12 (2000), 205–213. |
[58] | P. Wong, G. M. Barton, K. A. Forbush et al., Dynamic tuning of T cell reactivity by self-peptide-major histocompatibility complex ligands, J. Exp. Med., 193 (2001), 1179–1187. |
[59] | A. D. Bitmansour, D. C. Douek, V. C. Maino, et al., Direct ex vivo analysis of human CD4+ memory T cell activation requirements at the single clonotype level, J. Immunol., 169 (2002), 1207–1218. |
[60] | I. Stefanová, J. R. Dorfman and R. N. Germain, Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes, Nature, 420 (2002), 429–434. |
[61] | G. Altan-Bonnet and R. N. Germain, Modeling T cell antigen discrimination based on feedback control of digital ERK responses, PLoS Biol., 3 (2005), e356. |
[62] | H. A. van den Berg and D. A. Rand, Dynamics of T cell activation threshold tuning, J. Theor. Biol., 228 (2004), 397–416. |
[63] | A. Scherer, A. Noest and R. J. de Boer, Activation-threshold tuning in an affinity model for the T-cell repertoire, Proc. R. Soc. Lond. B Biol. Sci., 271 (2004), 609–616. |
[64] | A. R. McLean, Modelling T cell memory, J. Theor. Biol., 170 (1994), 63–74. |
[65] | C. Utzny and N. J. Burroughs, Perturbation theory analysis of competition in a heterogeneous population, Physica D, 175 (2003), 109–126. |
[66] | N. J. Burroughs, B. M. P. M. de Oliveira and A. A. Pinto, Regulatory T cell adjustment of quorum growth thresholds and the control of local immune responses, J. Theor. Biol., 241 (2006), 134–141. |
[67] | N. J. Burroughs, B. M. P. M. Oliveira, A. A. Pinto, et al., Sensibility of the quorum growth thresholds controlling local immune responses, Math. Comput. Model., 47 (2008), 714–725. |
[68] | A. L. DeFranco, R. M. Locksley and M. Robertson, Immunity: The immune response in infectious and inflammatory disease, New Science Press Ltd., 2007. |
[69] | A. Toda and C. A. Piccirillo, Development and function of naturally occurring CD4+CD25+ regulatory T cells, J. Leukoc. Biol., 80 (2006), 458–470. |
[70] | P. S. Kim, P. P. Lee and D. Levy, Modeling regulation mechanisms in the immune system, J. Theor. Biol., 246 (2007), 33–69. |
[71] | B. M. P. M. Oliveira, R. Trinchet, M. V. O. Espinar, et al., Modelling the suppression of autoimmunity after pathogen infection, Math. Meth. Appl. Sci., 41 (2018), 8565–8570. |
[72] | J. Tam, Delay effect in a model for virus replication, IMA J. Math. Appl. Med. Biol., 16 (1999), 29–37. |
[73] | R. V. Culshaw and S. Ruan, A delay-differential equation model of HIV infection of CD4+ T-cells, Math. Biosci., 165 (2000), 27–39. |
[74] | P. W. Nelson and A. S. Perelson, Mathematical analysis of delay differential equation models of HIV-1 infection, Math. Biosci., 179 (2002), 73–94. |
[75] | X. Zhou, X. Song and X. Shi, Analysis of stability and Hopf bifurcation for an HIV infection model with time delay, Appl. Math. Comput., 199 (2008), 23–38. |
[76] | A. J. Yates, M. Van Baalen and R. Antia, Virus replication strategies and the critical CTL numbers required for the control of infection, PLoS Comput. Biol., 7 (2011), e1002274. |
[77] | G. J. M. Webster, S. Reignat, M. K. Maini, et al., Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms, Hepatology, 32 (2000), 1117–1124. |
[78] | M. S. Ciupe, B. L. Bivort, D. M. Bortz, et al., Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models, Math. Biosci., 200 (2006), 1–27. |
[79] | M. P. Davenport, R. M. Ribeiro and A. S. Perelson, Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection, J. Virol., 78 (2004), 10096–10103. |
[80] | R. Thimme, J. Bukh, H. C. Spangenberg, et al., Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease, Proc. Natl. Acad. Sci. USA, 99 (2002), 15661–15668. |
[81] | K. B. Blyuss and L. B. Nicholson, The role of tunable activation thresholds in the dynamics of autoimmunity, J. Theor. Biol., 308 (2012), 45–55. |
[82] | K. B. Blyuss and L. B. Nicholson, Understanding the roles of activation threshold and infections in the dynamics of autoimmune disease, J. Theor. Biol., 375 (2015), 13–20. |
[83] | D. Ben Ezra and J. V. Forrester, Fundal white dots: the spectrum of a similar pathological process, Br. J. Ophthalmol., 79 (1995), 856–860. |
[84] | T. F. Davies, D. C. Evered, B. Rees Smith, et al., Value of thyroid-stimulating-antibody determination in predicting the short-term thyrotoxic relapse in Graves' disease, Lancet, 309 (1997), 1181–1182. |
[85] | A. Nylander and D. A. Hafler, Multiple sclerosis, J. Clin. Invest., 122 (2012), 1180–1188. |
[86] | F. Fatehi, Y. N. Kyrychko, R. Molchanov, et al., Bifurcations and multi-stability in a model of cytokine-mediated autoimmunity, Int. J. Bif. Chaos, 29 (2019), 1950034. |
[87] | F. Fatehi, Y. N. Kyrychko and K. B. Blyuss, Effects of viral and cytokine delays on dynamics of autoimmunity, Mathematics, 6 (2018), 66. |
[88] | F. Fatehi, S. N. Kyrychko, A. Ross, et al., Stochastic effects in autoimmune dynamics, Front. Physiol., 9 (2018), 45. |
[89] | D. A. Copland, M. S. Wertheim, W. J. Armitage, et al., The clinical time-course of Experimental Autoimmune Uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation, Invest. Ophthalmol. Vis. Sci., 49 (2008), 5458–5465. |
[90] | J. Boldison, T. K. Khera, D. A. Copland, et al., A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis, Immunology, 146 (2015), 301–311. |
[91] | P. Krishnapriya and M. Pitchaimani, Analysis of time delay in viral infection model with immune impairment, J. Appl. Math. Comput., 55 (2017), 421–453. |
[92] | S. D. Wolf, B. N. Dittel, F. Hardardottir, et al., Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice, J. Exp. Med., 184 (1996), 2271–2278. |
[93] | H. J. Wu, I. I. Ivanov, J. Darce, et al., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells, Immunity, 32 (2010), 815–827. |
[94] | I. Baltcheva, L. Codarri, G. Pantaleo, et al., Lifelong dynamics of human CD4+CD25+ regulatory T cells: Insights from in vivo data and mathematical modeling, J. Theor. Biol., 266 (2010), 307–322. |
[95] | J. Li, L. Zhang and Z. Wang, Two effective stability criteria for linear time-delay systems with complex coefficients, J. Syst. Sci. Complex., 24 (2011), 835–849. |
[96] | B. Rahman, K. B. Blyuss and Y. N. Kyrychko, Dynamics of neural systems with discrete and distributed time delays, SIAM J. Appl. Dyn. Syst., 14 (2015), 2069–2095. |
[97] | A. Skapenko, J. Leipe, P. E. Lipsky, et al., The role of the T cell in autoimmune inflammation, Arthritis Res. Ther., 7(Suppl 2) (2005), S4–S14. |
[98] | R. Antia, V. V. Ganusov and R. Ahmed, The role of models in understanding CD8+ T-cell memory, Nat. Rev. Immunol., 5 (2005), 101–111. |
1. | Lu Xu, Chunlai Mu, Qiao Xin, Global boundedness and asymptotic behavior of solutions for a quasilinear chemotaxis model of multiple sclerosis with nonlinear signal secretion, 2023, 28, 1531-3492, 1215, 10.3934/dcdsb.2022118 |